Stay updated with breaking news from Tas 102. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Arvind N. Dasari, MD, MS, provides a comprehensive overview of the FRESCO-2 trial investigating fruquintinib in patients with refractory metastatic colorectal cancer.
A panel of experts on colorectal cancer have a comprehensive discussion on adverse events associated with TAS-102 plus bevacizumab and strategies to mitigate them.
1. The median overall survival was 10.8 months in the combination group (FTD–TPI + bevacizumab) and 7.5 months in the FTD–TPI alone group, with HR 0.61. 2. The most common adverse events in both groups included neutropenia, nausea, and anemia. Evidence Rating Level: 1 (Excellent) Study Rundown: Trifluridine-tipiracil (cytotoxic nucleic acid analogue) is commonly used
The FDA has accepted for priority review the supplemental new drug application seeking the approval of trifluridine/tipiracil as a single agent or in combination with bevacizumab for use in select patients with refractory, metastatic colorectal cancer.